Anson Funds Management LP → MEI Pharma, Inc. LITS

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 6/100

Passive Schedule 13G filer baseline

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

108,535 shares short · -41.4% vs prior

Other 13D/G Filings on MEI Pharma, Inc.

Filed	Form	Filer	Stake	Shares
2023-07-17	SC	Anson Funds Management LP	—	—	view →
2019-12-30	SC	Growth Equity Opportunities V, LLC	—	—	view →

Other Filings by Anson Funds Management LP

Filed	Form	Issuer	Stake	Shares
2023-07-17	SC	MEI Pharma, Inc. LITS	—	—	view →
2023-05-02	SC	Nano Dimension Ltd. NNDM	—	—	view →
2022-04-18	SC	Amarantus Bioscience Holdings, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →